NVCR News and Press, NovoCure Limited From 02/23/23

Dr. Ocean, a medical oncologist and Associate Professor of Clinical Medicine at Weill Cornell Medicine, brings decades of experience in oncology to Novocure Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors. ...

Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of pivotal PANOVA-3 study...

NovoCure ( NASDAQ: NVCR ) is scheduled to announce Q4 earnings results on Thursday, February 23rd, before market open. The consensus EPS Estimate is -$0.29 and the consensus Revenue Estimate is $127.2M (-4.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward rev...

In the biotech world, investors often heave a sigh of relief when an important clinical goal is met. That was the case Wednesday with oncology specialist Novocure (NASDAQ: NVCR) , which enjoyed an almost 2% rise in its share price on the day, beating the S&P 500 index's 0.3% gain....

Final data from the PANOVA-3 study anticipated in 2024 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of...

Summary As NovoCure Limited delivers hope in seemingly hopeless situations, Tumor Treating Field is already launched for mesothelioma and glioblastoma multiforme. NovoCure Limited recently generated stellar data for the Phase 3 (LUNAR) trial for non-small cell lung cancer. Amid grea...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...

Summary Healthcare is considered a defensive sector and due to the brand name and cheap exposure, Vanguard's ETF prima-facie looks like a promising idea. However, outsized exposure to pharmaceuticals and biotechnology makes VHT a high beta healthcare ETF, undermining its defensive quali...

Novocure ( NASDAQ: NVCR ) said Chief Medical Officer Ely Benaim will step down and leave the company. The company added that the decision was made after a review of Novocure's future needs and that the organizational changes are effective Jan. 17. Piet Hinoul, curren...

Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17. Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new executive role as Chief Growth Officer. In this role, Mr. Shah will have worldwide responsibilit...